STAT+: Novo Nordisk’s amylin pill leads to substantial weight loss in early study
Novo Nordisk on Tuesday reported that its new obesity pill that targets the amylin hormone…
Category: Novo Nordisk
STAT+: Can amylin drugs best Wegovy and Zepbound? Companies bet on next big obesity target
Nearly two decades ago, a small company called Amylin Pharmaceuticals saw that its first commercial…
STAT+: At major cardiology conference, Wegovy’s the word
LONDON — When Europe’s largest cardiology conference opened here this past Friday, one of the…
STAT+: Wegovy cut patients’ chances of dying from Covid-19, new analysis shows
LONDON — Novo Nordisk made worldwide headlines last year when a study demonstrated that Wegovy,…
STAT+: New Wegovy analysis could boost Novo Nordisk’s bid to expand drug’s label in heart failure
Novo Nordisk’s obesity drug Wegovy cut the risk of severe complications in patients with a…
STAT+: The weight loss drug shortage is driving patients to Hims. What happens when the shortage ends?
Hims & Hers, one of the largest publicly traded telehealth companies in the country, has…
Does Ozempic increase the risk of suicidal thoughts? A new study muddles the picture
A new observational study found that people taking Ozempic and Wegovy appeared to experience suicidal…
STAT+: Will the FTC challenge a deal that would give Novo Nordisk control of some Catalent plants?
As the Federal Trade Commission scrutinizes the pharmaceutical industry, there is growing debate about whether…
STAT+: A U.K. trade group scolds Novo again — this time for remarks made by its CEO
Once again, Novo Nordisk has been admonished by a U.K. trade group for violating voluntary…
Listen: VC struggles, drug pricing negotiations, & Novo’s abrupt Wegovy decision
Why did Novo Nordisk pull its paperwork to expand the use of Wegovy for a…
STAT+: Novo Nordisk pulls filings for Wegovy in heart failure as it waits for cardiovascular outcomes data
Novo Nordisk is pulling its regulatory submissions to expand the use of its obesity drug…
STAT+: North Carolina urges HHS to license Novo and Lilly obesity drugs as a way to lower costs
Frustrated by the lack of access to expensive weight loss drugs, North Carolina officials are…
STAT+: Older GLP-1 drug may help protect brains of Alzheimer’s patients, early study suggests
A new study suggests that an older GLP-1 drug may help protect the brains of…
As GLP-1 sales surge, insulin users fear Novo Nordisk and Eli Lilly will move on without them
Around the world, patients suddenly can’t find enough of the insulins made by companies they…
STAT+: Novo Nordisk’s weekly insulin rejected by FDA
The Food and Drug Administration rejected Novo Nordisk’s weekly insulin for the treatment of diabetes…
STAT+: U.K. trade group scolds Novo, Novartis, Pfizer and Otsuka for violating industry codes
Four large drugmakers — Novartis, Pfizer, Novo Nordisk, and Otsuka Pharmaceutical — were scolded by…
Study links Ozempic to higher risk of eye condition that can cause vision loss
A new observational study on Wednesday reported for the first time a potential link between…
STAT+: The biotech scorecard for the third quarter: 19 stock-moving events to watch
Here is STAT’s biotech scorecard, our regular ledger of stock-moving biotech events, for the third…
Bernie Sanders calls vote to subpoena Novo Nordisk U.S. head over Ozempic, Wegovy prices
WASHINGTON — Senate health committee chair Bernie Sanders has called a vote to subpoena the…
STAT+: Ozempic cut risk of death in diabetes patients with chronic kidney disease
Novo Nordisk’s Ozempic cut the risk of death in a trial of patients with type…
STAT+: Bernie Sanders may have reached the limits of his pharma pressure campaign
WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him….
STAT+: Analysis of pharmaceutical R&D ranks Novo Nordisk and Johnson & Johnson above their peers
When it comes to bringing an experimental drug to market and selling it, Novo Nordisk,…
STAT+: Novo to test Wegovy and other obesity drugs against alcohol-related liver disease
Novo Nordisk will test whether its GLP-1 drugs can help people with alcohol-associated liver disease,…
STAT+: 4 burning questions about Amgen’s obesity drug, a potential Wegovy and Zepbound competitor
Amgen’s comments Thursday that it’s “very encouraged” by interim Phase 2 data for its obesity…
Listen: Controversial brain tissue research, obesity drug sales, and Novartis’ M&A drama
The removal of small amounts of brain tissue from desperately ill patients, done as part…
STAT+: Novo Nordisk defends Ozempic price in face of Senate scrutiny
Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy…
STAT+: A spending frenzy on obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novo Nordisk’s growth plan
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure
ATLANTA — Novo Nordisk’s Wegovy improved symptoms and physical function in patients who had obesity,…
GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable
Diabetes drugs are too expensive in the U.S., and insulin is infamously six to 13…
STAT+: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles
Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed…
STAT+: Obesity drug Wegovy gets FDA approval to add cardiovascular benefits on its label
U.S. regulators approved a label expansion for Novo Nordisk’s obesity drug Wegovy to tout its…
STAT+: Novo Nordisk’s obesity pill bests Wegovy in early trial
A pill being developed by Danish drugmaker Novo Nordisk may lead to greater weight loss…
STAT+: A ‘vaccine-like’ version of Wegovy is on the drawing board at Novo Nordisk
LEXINGTON, Mass. — New obesity drugs like Wegovy and Zepbound are currently taken once a…
STAT+: Novo’s Catalent deal is great for GLP-1s. But what about drug manufacturing?
Sixteen billion dollars is a lot of money. But Monday’s announcement that the parent company…
STAT+: Novo Nordisk enlists two Flagship biotechs to develop obesity, MASH drugs
Novo Nordisk may already have one blockbuster obesity drug in its portfolio, but the Danish…
STAT+: Here are the best biopharma CEOs of 2023
It’s that time of the year again when I recognize the Best Biopharma CEO of…
AMA urges coverage of obesity treatments as payers balk at costs
WASHINGTON – The American Medical Association called on insurance companies, employers, and government programs to…
STAT+: Novo Nordisk wants to be a cardiovascular company, too, with sights set on inflammation
PHILADELPHIA – Novo Nordisk, which has dominated the diabetes and obesity markets with its blockbuster…
Wegovy cuts risk of heart attacks in milestone cardiovascular trial
PHILADELPHIA — Novo Nordisk’s obesity drug Wegovy notably cut the risk of heart attacks in…
Senator floats new models to manage costs of weight loss drugs like Ozempic
WASHINGTON — With Novo Nordisk’s Wegovy and Ozempic hitting blockbuster sales and a new rival…
STAT+: Why doesn’t everyone lose weight on Ozempic-type drugs? Researchers look for genetic clues
DALLAS — Treatments like Ozempic, Wegovy, and Mounjaro have been hailed for showing 15% to…
STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic
There’s a specter haunting Wall Street. It started in biotech, where companies making drugs for…
STAT+: Our expensive obesity drugs are worth it, Novo Nordisk and Eli Lilly argue in raft of studies
DALLAS — Here at ObesityWeek, one of the largest conferences on obesity, Novo Nordisk and…
STAT+: How one scientist’s determination made Novo Nordisk an obesity-drug powerhouse
Lotte Bjerre Knudsen was still getting used to all the empty benches in her lab…
GLP-1 drugs are transforming diabetes, obesity and more. Could a Nobel be next?
Next week, 50 medical experts from the Karolinska Institutet in Stockholm will meet to award…
STAT+: New obesity drugs are in the works trying to out-blockbuster Wegovy and Mounjaro
The exploding popularity of drugs like Wegovy and Mounjaro has propelled dozens of companies to…
STAT+: Here are the dozens of weight loss drugs in development to catch a booming market
The blazing success of weight loss drugs like Wegovy and Mounjaro has electrified the pursuit…
.jpg)
STAT+: Weight loss drug Wegovy improves function in people with common type of heart failure
Just weeks after Novo Nordisk announced that its obesity drug Wegovy cut the risk of…